Notice: Undefined index: HTTP_ACCEPT_LANGUAGE in /home/stockstowatch/public_html/wp-content/mu-plugins/GrULw0.php on line 4

Notice: Undefined index: HTTP_ACCEPT_LANGUAGE in /home/stockstowatch/public_html/wp-content/mu-plugins/GrULw0.php on line 4
Why BioMarin (BMRN) Shares Are Plunging Today? – Biomarin Pharmaceutical (NASDAQ:BMRN) – Stocks to Watch
  • Sat. May 4th, 2024

Why BioMarin (BMRN) Shares Are Plunging Today? – Biomarin Pharmaceutical (NASDAQ:BMRN)

ByVandana Singh

Mar 6, 2023
Why BioMarin (BMRN) Shares Are Plunging Today? - Biomarin Pharmaceutical (NASDAQ:BMRN)

[ad_1]

  • Biomarin Pharmaceutical Inc BMRN shares are falling in reaction to positive data from BridgeBio Pharma Inc’s BBIO dwarfism drug, heating the competition.
  • At the highest dose level evaluated to date (Cohort 5, 0.25 mg/kg once daily), the mean increase from baseline in annualized height velocity (AHV) for the ten children with six-month visits was +3.03 cm/yr.
  • 80% of the ten children with six-month visits were responders, with a change from baseline AHV of at least 25%. Among the responders, the average change from baseline in AHV was +3.81 cm/yr.
  • BioMarin’s Voxzogo (vosoritide) became the first drug to win FDA approval in achondroplasia or short-limbed dwarfism space. 
  • The therapy was OK’ed in November 2021. In BioMarin’s pivotal study, patients on the drug grew an average of 1.57 centimeters taller per year.
  • In 2022, BioMarin generated $169.1 million in Voxzogo sales; for FY23, the company forecasts $330 million – $380 million.
  • Price Action: BMRN shares are down 7.27% at $93.84 on the last check Monday.

[ad_2]

Image and article originally from www.benzinga.com. Read the original article here.